← Back to Search

Antimuscarinic Agent

Solifenacin for Urinary Symptoms Post-Prostate Surgery

Phase 4

Waitlist Available

Led By Jeffrey M Frankel, MD

Research Sponsored by Seattle Urology Research Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients may be included if they have previously been treated with FDA approved anticholinergic agents for the treatment of OAB such as Oxybutynin chloride, Tolterodine tartrate, or trospium chloride and are no longer receiving such treatment for a minimum of 14 days prior to study

Male patients greater than 18 years of age with continued OAB symptoms after successful PVP for BPH

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

Study Summary

This trial will show that the drug solifenacin can help with urinary symptoms after a GreenLight laser surgery that improves obstructive symptoms.

Who is the study for?

Men over 18 with ongoing Overactive Bladder (OAB) symptoms after successful prostate surgery using GreenLight laser can join. They must have stopped any previous OAB treatments like Oxybutynin for at least 14 days. Those with bladder stones, cancer, infections, certain urinary issues, hypersensitivity to Solifenacin or similar drugs, recent trial participation or conditions that may risk safety are excluded.Check my eligibility

What is being tested?

The study is testing if the drug Solifenacin can improve irritative bladder symptoms such as nighttime urination and urgency in men who've had a specific prostate procedure. It's for those whose blockage was cleared but still experience discomfort.See study design

What are the potential side effects?

Solifenacin might cause dry mouth, constipation, blurred vision and dizziness due to its anticholinergic effects. Some people could also experience mild stomach upset or fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have stopped taking my OAB medication for at least 14 days.

Select...

I am a man over 18 with ongoing bladder issues after prostate surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dysuria

Secondary outcome measures

Change in mean nocturia episodes/24 hours based on 3 day diary

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Seattle Urology Research CenterLead Sponsor

Jeffrey M Frankel, MDPrincipal InvestigatorSeattle Urology Research Center

Media Library

Solifenacin (Antimuscarinic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT00826527 — Phase 4

Nocturia Clinical Trial 2023: Solifenacin Highlights & Side Effects. Trial Name: NCT00826527 — Phase 4

Solifenacin (Antimuscarinic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00826527 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks does this treatment pose for individuals?

"Assuredly, our team at Power assigns this treatment a score of 3 due to the fact that its Phase 4 trial status implies it has been approved."

Answered by AI

Are there currently any opportunities for participants to join this research project?

"Clinicaltrials.gov reports that this clinical trial is no longer recruiting patients; the initial post date was on January 1st 2007 and it most recently updated on January 21st 2009. Alternatively, 15 other trials are currently seeking participants for their respective studies."

Answered by AI